Next Day Disclosure Return
Filed with HKEX · Stock code 6938 · · 6 pages · English
Suzhou Ribo Life Science Co. Ltd. on 6ix
Earlier from Suzhou Ribo Life Science
- Voluntary announcement - phase I clinical trial application submission of novel dual targeting siRNA SR122 for treatment of mixed dyslipidemia and severe hypertriglyceridemia
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Discloseable and connected transaction acquisition of the remaining 49.71% shareholding in a subsidiary involving the issue of consideration shares under Specific mandate; and proposed change of registered capital and amendments to the articles of association
Follow Suzhou Ribo Life Science into a list and get an email when it puts out news.
Follow Suzhou Ribo Life Science